Drug
BI 771716
BI 771716: highest development phase Phase 2, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BI 771716 NCT06722157 | Phase 2 | Macular Degeneration, Age-related |
Latest
No recent events.
Follow BI 771716 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.